| Bibliographic Citation
| - Trotman Judith, Barrington Sally F, Belada David, Meignan Michel, MacEwan Robert, Owen Carolyn, Ptáčn'ik Václav, Rosta András, Fingerle-Rowson Günter R, Zhu Jiawen, Nielsen Tina, Sahin Deniz, Hiddemann Wolfgang, Marcus Robert E, Davies Andrew, Hertzberg Mark, Grigg Andrew, Cannell Paul, Quach Hang, Opat Stephen, Tam Constantine, Marlton Paula, Janssens Ann, Offner Fritz, Van Eygen Koen, Sangha Randeep, Mckay Pam, Wilson Jonathan, Van Der Jagt Richard, Roitman Daryl, Trneny Marek, Mayer Jiri, Le Du Katell, Solal-Celigny Philippe, Cartron Guillaume, Foussard Charles, Frickhofen Norbert, Schmidt Peter, Graeven Ullrich, Gaska Tobias, Schlag Rudolf, Sökler Martin, Prange-Krex Gabriele, Florschütz Axel, Lindemann Hans-Walter, Schimmelpfennig Christoph, Tonndorf Solveig, Hänel Mathias, Hess Georg, Schalk Enrico, Hütten Heiko, Doelken Gottfried, Pfreundschuh Michael, Keller Ulrich, Herold Michael, Forstpointner Roswitha, Vehling-Kaiser Ursula, Hoffmann Martin, Borbényi Zita, Udvardy Miklos, Demeter Judit, Rambaldi Alessandro, Morra Enrica, Massimo Federico, Majolino Ignazio, Balzarotti Monica, Semenzato Gianpietro, Canales Albendea Miguel Angel, Peñalver Parraga Francisco Javier, Soler Campos Alfonso, Sancho Cia Juan Manuel, Marquez Navarro Jose Antonio, Grande Garcia Carlos, Nilsson-Ehle Herman, McCarthy Helen, Pocock Chris, Sadullah Shalal, Malladi Ram, Radford John, Kanfer Ed, Kruger Anton, Culligan Dominic, Dyer Martin, Pettengell Ruth, Seymour John, Gribben John, Al-Ismail Saad, Al-Refaie Faris, Blesing Norbert, Macnamara Christopher, O'callaghan Ann, Haynes Andrew, Follows George, Johnson Roderick, Cunningham David, Bowles Kristian, Collins Graham, Gallop-Evans Eve, Robinson Stephen, Subash Chezhian, Bailey James, Holden Viran, Neidhart Jeffrey, De Oliveira Moacyr, Tezcan Haluk, Kim Kevin, Kambhampati Suman, Lanier Keith, Mcclean John, Tobinai Kensei. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncology, Elsevier, 2018, 19 (11), pp.1530--1542. ⟨10.1016/S1470-2045(18)30618-1⟩
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
